Iothalamic Acid

Summary

Iothalamic Acid (CHEMBL1201300) is an approved small molecule (ATC V08AA04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA04
• Chemistry: 613.91 Da · C11H9I3N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201300
Name	Iothalamic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3737
ATC	V08AA04
Molecular formula	C11H9I3N2O4
Molecular weight	613.91
InChIKey	UXIGWFXRQKWHHA-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I

IUPAC name: 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid

Also known as: Acide iotalamique, Acido iotalamico, Iotalamic acid, Iothalamate, Iothalamic acid, MI-216, NSC-759891, iothalamate, IOTHALAMIC ACID, IOTHALAMIC ACID-D3, Iothalamic_acid-d3

Parent form; salt/anhydrous children: CHEMBL1097620, CHEMBL1201123, CHEMBL1201125, CHEMBL2104998, CHEMBL2106318, CHEMBL5308402

Patent coverage: 731 distinct patent families (2,203 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,177 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).